These studies demonstrated that ALK TKIs combined with MEK TKIs targeting ALK-positive lung cancer cells have superior efficiency at suppressing cell growth, which provides an alternative approach for treating ALK-positive patients. This evidence concerns the gene ALK and lung carcinoma.